礼来中国总经理德赫兰表示，此次更新在保障疗效的同时显著提升了安全性，是阿尔茨海默病治疗的重 要进展。此举旨在为中国早期症状性阿尔茨海默病患者提供更安全、可控的治疗选择，推动疾病进入长 程管理的新时代。 经济观察网礼来公司宣布，其每月一次的阿尔茨海默病治疗药物记能达(多奈单抗)已获中国国家药监局 批准更新说明书，采纳新的推荐剂量滴定方案。该新方案采用更渐进的滴定方式。关键临床研究 (TRAILBLAZER-ALZ6)数据显示，新方案在第24周和第52周，能将淀粉样蛋白相关性影像异常(ARIA- E，一种常见副作用)的发生率分别显著降低41%和35%，同时保持了与原方案相当的淀粉样蛋白斑块清 除效果。 ...

Core Viewpoint - West Point Pharmaceutical has announced that its oral solution of Rivastigmine Tartrate for the treatment of mild to moderate Alzheimer's disease will be launched in 2025, aiming to capture long-term opportunities arising from an aging population [1][2]. Group 1: Company Strategy and Product Development - The company is focusing on the "silver economy" strategy, which includes introducing new products and redeveloping existing ones, with a capitalized cooperation model with Shandong Langnuo Pharmaceutical for Rivastigmine Tartrate [2][4]. - West Point Pharmaceutical aims to build a product matrix for elderly care, targeting chronic diseases prevalent among the elderly, and enhancing product development efficiency through strategic partnerships [4][5]. Group 2: Financial Performance - Since its listing in February 2022, West Point Pharmaceutical has shown lackluster performance, with a revenue of 256 million yuan in 2024, a year-on-year increase of 13.71%, but a net profit decline of 20.26% to 40 million yuan [3]. - For the first nine months of 2025, the company reported a revenue of 189 million yuan, a decrease of 1.89%, and a net profit of 33 million yuan, down 2.70% year-on-year [4]. Group 3: Product Details and Market Context - Rivastigmine Tartrate, initially developed by Novartis, is a third-generation acetylcholinesterase inhibitor used for treating Alzheimer's disease, first launched in Switzerland in 1997 and approved in China in 2000 [8][9]. - The drug is currently one of the most effective treatments for Alzheimer's, but its market price is high, with domestic production by multiple companies including Shandong Langnuo and Zhejiang Kairun [11][14].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 学习 通常指知识的获取， 记忆 则是保留信息的能力，这两项是人类大脑的基本功能，受特定脑区神经递质/神经肽信号的调控。这些神经递质/神经肽的耗竭或 其受体表达的减少，尤其是在老年人中，可能会导致记忆障碍。 胆囊收缩素 （CCK） 是大脑中含量最丰富的神经肽之一，分布于新皮质、杏仁核、丘脑、海马体和内嗅皮质 （EC） 。CCK 参与神经递质传递，并调控许多大 脑功能，如情绪、学习和记忆、焦虑以及恐惧。重要的是，内嗅皮层是富含 CCK 的大脑区域，它充当海马体与新皮质之间信息传递的中介。 CCK 通过与 B 型 胆囊收缩素受体 （CCKBR） 的特异性结合发挥核心作用， 这一作用不仅对长时程增强 （LTP） 至关重要， 并对于声音 - 声音联想记忆也很重要，这是学习和 记忆的一个重要方面。 然而，大脑中有多种 CCK 亚型，它们能够激活多种 G 蛋白亚型信号，包括但不限于 Gs、Gq 和 Gi，其中 硫酸化 CCK8 （CCK8s） 最为丰富。此前的研究显 示，外源性 CCK8s 能够显著改善老年大鼠的空间学习记忆能力，这提示了 调控 CCK 信号通路 有治疗阿尔茨海默病的 ...

Core Insights - Eli Lilly and Company (India) has received approval from the Central Drugs Standard Control Organization (CDSCO) for donanemab, a drug aimed at treating Alzheimer's disease in adults with early symptomatic stages [1][2] - The approval is seen as a significant milestone in addressing the urgent needs of individuals living with Alzheimer's disease in India [2] - Donanemab is designed to target amyloid plaques and slow cognitive decline, potentially improving the quality of life for patients and their families [3] Industry Context - Alzheimer's disease is the most common cause of dementia globally, accounting for 60-70% of dementia cases [3] - The disease remains highly underdiagnosed in India, with projections indicating that over 8 million people will be living with dementia in the country by 2030, with Alzheimer's representing the largest share of these cases [4]

Core Viewpoint - The company is advancing its innovative drug, Succinyl-8-hydroxyl-aminocarbazole tablets, aimed at treating Alzheimer's disease, which is expected to support its strategic goals of Asianization of traditional Chinese medicine and internationalization of chemical drugs [1]. Group 1 - The company has completed all professional review work for the new chemical drug and is currently in the comprehensive review phase, with all evaluations proceeding normally [1]. - The company plans to continue its deep layout in the neurological product pipeline and platform construction [1]. - Relevant information regarding the new drug will be disclosed according to regulations and requirements, and investors are encouraged to pay attention to company announcements [1].

编辑丨王多鱼 排版丨水成文 撰文丨王聪 阿尔茨海默病 （AD） 是最常见的神经退行性疾病，目前尚无有效的治疗方法。细胞外淀粉样斑块、神经原纤维缠结、 神经炎症以及神经元丢失是阿尔茨海默病神经病理学的特征。 β- 淀粉样蛋白 （Aβ） 是淀粉样斑块的主要成分，它是通过 β-分泌酶 BACE1 和 γ-分泌酶对 淀粉样前体蛋白 （APP） 进行连续切割而产生的。 APP、BACE1 和 γ-分泌酶的失调会增加 Aβ 的生成，而小胶质细胞的功能障碍会 降低对 Aβ 的清除，从而导致 Aβ 的沉积。Aβ 沉积的增加反过来会激活小胶质细胞，促进大量促炎细胞因子的分泌。 肠道微生物群及其代谢物的失调在阿尔茨海默病 （AD） 的发病机制中发挥着关键作用。 丁酸 （Butyrate） 是一种短 链脂肪酸 （SCFA） ，主要由肠道细菌通过膳食纤维的发酵产生，具有多种生理功能，包括调节肠道健康、抗炎和神经 保护作用。近年来，研究发现丁酸在大脑健康及神经退行性疾病 （例如阿尔茨海默病） 中可能发挥有益作用。 提高丁 酸的生物利用度，对于其临床应用至关重要。 2025 年 11 月 17 日，温州医科大学/瓯江实验室 吴伊丽 教授 ...

Financial Data and Key Metrics Changes - For Q3 2025, the company generated total revenue of $2.8 million, with $2.3 million from net product sales of ZUNVEYL and $507,000 from licensing revenue [11] - Total operating expenses were $8.2 million, including $633,000 in cost of goods sold, reflecting an increase from $2.5 million in operating expenses in Q3 2024 [11] - The net loss was reported at $1.3 million, or $0.08 basic loss per share, an improvement from a net loss of $1.9 million, or $0.31 per share, in the previous year [12] Business Line Data and Key Metrics Changes - ZUNVEYL sales showed significant growth, with ex-factory purchases rising 44% from Q2 to Q3, and demand sales bottles dispensed growing 102% [15] - The company engaged with 2,038 homes in Q3, with 605 homes ordering ZUNVEYL, and 70% of those homes placing repeat orders [16] Market Data and Key Metrics Changes - The company anticipates continued sequential growth in ZUNVEYL's sales as awareness and payer access expand through 2026 [13] - The average of 16 years of industry experience among sales representatives is driving clinical education and adoption across the long-term care market [18] Company Strategy and Development Direction - The company plans to invest in sales, marketing, and research for ZUNVEYL, particularly focusing on behavioral symptoms associated with Alzheimer's [5] - The company is also advancing its sublingual formulation and anticipates running a comparative PK study in Q1 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ZUNVEYL's potential, highlighting the drug's clinically meaningful benefits across cognitive and behavioral symptoms [10] - The company remains focused on executing its commercial strategy and maintaining financial discipline to create long-term value for shareholders [14] Other Important Information - The company raised approximately $38 million in net proceeds through an equity offering in October, strengthening its balance sheet [12] - The company expects to initiate two studies in long-term care settings in Q4 2025 and Q1 2026 to assess ZUNVEYL's cognitive benefits and tolerability [9] Q&A Session Summary Question: Current status of contracting discussions and GPO agreements for ZUNVEYL - The company has one contract with a major PBM and is close to finalizing another by the end of the quarter, targeting four key Medicare plans [23][24] Question: Coverage without restrictions - Currently, about 15% of the signed plan has adopted ZUNVEYL without restrictions, with more visibility expected in the coming quarters [25] Question: Breakdown of unique prescribers and repeat orders - In Q3, 576 prescribers wrote orders, with 62% writing multiple orders, and 70% of homes placing repeat orders [27][28] Question: Key marketing messages resonating with prescribers - The most impactful messages include ZUNVEYL's effect on behaviors and its lack of impact on sleep, which is a significant concern for prescribers [31][32] Question: Sales cycle and prescriber interactions - The sales cycle remains initially slow, but once prescribers gain confidence, they tend to increase their patient base more rapidly [41]

Core Viewpoint - Shijiazhuang Yiling Pharmaceutical Co., Ltd. has received approval for the listing application of Memantine Hydrochloride, a chemical raw material drug, which is expected to enhance the company's product line and market share in the Alzheimer's treatment sector [1][2]. Group 1: Approval Notification - The approval notification was issued by the National Medical Products Administration for the chemical raw material drug Memantine Hydrochloride, submitted by the company's wholly-owned subsidiary, Hengtai Wanyuan Pharmaceutical Co., Ltd. [1] - The registration number for the drug is Y20240000483, confirming that it meets the requirements for drug registration under Chinese law [1]. Group 2: Drug Overview - Memantine Hydrochloride is a non-competitive NMDA receptor antagonist used to treat moderate to severe Alzheimer's disease, blocking neuronal damage caused by elevated glutamate levels [2]. - According to the 2024 China Alzheimer's Disease Report, there are approximately 16.9 million dementia patients in China, with a prevalence rate of about 1.19% [2]. - The anti-dementia market in China is valued at 1.56 billion yuan, with Memantine being a first-line treatment drug holding a market share of 22% [2]. - The market capacity for Memantine Hydrochloride in China is expected to reach 340 million yuan by 2025, with a year-on-year growth of 11% [2]. Group 3: Impact on the Company - The approval of Memantine Hydrochloride allows the company to sell the drug in the domestic market, enriching its product line and expanding its business scope [3]. - Currently, the approval is not expected to have a significant impact on the company's immediate operating performance [3].

Group 1 - Yiling Pharmaceutical's subsidiary Hengshui Wanyang received approval from the National Medical Products Administration for the listing application of Memantine Hydrochloride, a drug used to treat moderate to severe Alzheimer's disease [1] - Memantine Hydrochloride is a non-competitive NMDA receptor antagonist that blocks pathological increases in glutamate concentration, preventing neuronal damage [1] - The Alzheimer's disease report of 2024 indicates approximately 16.9 million dementia patients in China, with a prevalence rate of about 1.19‰, which is rapidly increasing due to population aging [1] Group 2 - The anti-dementia market in China is valued at 1.56 billion yuan, with Memantine being a first-line treatment drug holding a market share of 22% [1] - The market capacity for Memantine Hydrochloride in China is expected to reach 340 million yuan by 2025, with a year-on-year growth of 11%, and sales volume projected to be 160 million tablets, reflecting a 19% increase [1] - Yiling Pharmaceutical aims to enhance its market share following the domestic approval of Memantine Hydrochloride, anticipating steady demand growth due to the aging population [1] Group 3 - Yiling Pharmaceutical also received approval for Anastrozole, a drug widely used for treating estrogen-related tumors, just days prior [2] - The company’s subsidiary Beijing Yiling Bio holds the formulation approval for Anastrozole tablets, which are expected to achieve integrated production of raw materials and formulations this year, enhancing market competitiveness [2] - Yiling Pharmaceutical plans to accelerate the international registration and overseas sales of Anastrozole raw materials, targeting markets in Europe and the United States [2]

Group 1 - Huzhou Bio plans to repurchase shares worth 100 million to 200 million yuan, using its own funds, to stabilize stock prices and incentivize core talent [1] - The repurchase will cover 409,837 to 819,672 shares, accounting for 0.44% to 0.88% of the total share capital, and will be completed within 12 months [1] Group 2 - Enrite Pharmaceuticals' new drug, Memantine Hydrochloride Orally Disintegrating Tablets, has been approved for the treatment of moderate to severe Alzheimer's disease [2] - This drug is a novel NMDA receptor antagonist that protects nerve cells and promotes cognitive function recovery, filling a gap in the domestic market for this dosage form [2] Group 3 - Novartis' Remibrutinib has received FDA approval for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic after H1 antihistamine treatment [3] - Remibrutinib is the first BTK inhibitor approved by the FDA for CSU, providing a new treatment option by targeting the BTK signaling pathway to inhibit the release of histamine and other pro-inflammatory mediators [3]